Evidence map›Paper›PMID 32059061›Full record

ArticleAngewandte Chemie (International ed. in English)2020

Continuous-Flow Synthesis of ZIF-8 Biocomposites with Tunable Particle Size.

Francesco Carraro, Jason D Williams, Mercedes Linares-Moreau, Chiara Parise, Weibin Liang, Heinz Amenitsch, Christian Doonan, C Oliver Kappe, Paolo Falcaro

Open access · hybridAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Continuous-Flow Synthesis of ZIF-8 Biocomposites with Tunable Particle Size.Angewandte Chemie (International ed. in English) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Francesco CarraroInstitute of Physical and Theoretical Chemistry, Graz University of Technology, Stremayrgasse 9, 8010, Graz, Austria.ORCID 0000-0001-8485-4676
Jason D WilliamsCenter for Continuous Flow Synthesis and Processing (CCFLOW), Research Center Pharmaceutical Engineering GmbH (RCPE), Inffeldgasse 13, 8010, Graz, Austria.ORCID 0000-0001-5449-5094
Mercedes Linares-MoreauInstitute of Physical and Theoretical Chemistry, Graz University of Technology, Stremayrgasse 9, 8010, Graz, Austria.ORCID 0000-0003-3027-6238
Chiara PariseInstitute of Chemistry, University of Graz, NAWI Graz, Heinrichstrasse 28, 8010, Graz, Austria.
Weibin LiangDepartment of Chemistry and Centre for Advanced Nanomaterials, The University of Adelaide, Adelaide, 5005, Australia.ORCID 0000-0002-3032-436X
Heinz AmenitschInstitute of Inorganic Chemistry, Graz University of Technology, Stremayrgasse 9, 8010, Graz, Austria.ORCID 0000-0002-0788-1336
Christian DoonanDepartment of Chemistry and Centre for Advanced Nanomaterials, The University of Adelaide, Adelaide, 5005, Australia.ORCID 0000-0003-2822-0956
C Oliver KappeCenter for Continuous Flow Synthesis and Processing (CCFLOW), Research Center Pharmaceutical Engineering GmbH (RCPE), Inffeldgasse 13, 8010, Graz, Austria.ORCID 0000-0003-2983-6007
Paolo FalcaroInstitute of Physical and Theoretical Chemistry, Graz University of Technology, Stremayrgasse 9, 8010, Graz, Austria.ORCID 0000-0001-5935-0409
Graz University of Technology · ATUniversity of Graz · ATThe University of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zeolitic imidazolate framework (ZIF) biocomposites show the capacity to protect and deliver biotherapeutics. To date, the progress in this research area is based on laboratory batch methods. Now, the first continuous flow synthetic method is presented for the encapsulation of a model protein (bovine serum albumin, BSA) and a clinical therapeutic (α1-antitrypsin, AAT) in ZIF-8. The in situ kinetics of nucleation, growth, and crystallization of BSA@ZIF-8 were studied by small-angle X-ray scattering. By controlling the injection time of ethanol, the particle growth could be quenched by ethanol-induced crystallization from amorphous particles to ZIF-8 crystals. The particle size of the biocomposite was tuned in the 40-100 nm range by varying residence time prior to introduction of ethanol. As a proof-of-concept, this procedure was used for the encapsulation of AAT in ZIF-8. Upon release of the biotherapeutic from the composite, the trypsin inhibitor function of AAT was preserved.

Indexed as

alpha 1-AntitrypsinAnimalsBiocompatible MaterialsCattleCrystallizationDrug CarriersDrug LiberationEthanolParticle SizeSerum Albumin, BovineZeolitesalpha 1-AntitrypsinBiocompatible MaterialsDrug CarriersEthanolSerum Albumin, BovineZeolitesflow chemistryin situ SAXSmetal-organic frameworksMOF biocompositesparticle size

Identifiers

PMID32059061
PMCPMC7318291
OpenAlexW3006159607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.